Aemetis, Inc. (NASDAQ:AMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Aemetis, Inc. (NASDAQ:AMTX) missed earnings with its latest first-quarter results, disappointing overly-optimistic forecasters. It was not a great result overall, as revenues of US$43m fell 27% short of analyst expectations. Unsurprisingly, statutory losses ended up being20% larger than the analysts expected, at US$0.47 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

After the latest results, the five analysts covering Aemetis are now predicting revenues of US$345.7m in 2025. If met, this would reflect a substantial 45% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 48% to US$0.83. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$351.9m and losses of US$1.39 per share in 2025. Although the revenue estimates have not really changed Aemetis'future looks a little different to the past, with a considerable decrease in the loss per share forecasts in particular.

See our latest analysis for Aemetis

These new estimates led to the consensus price target rising 83% to US$23.50, with lower forecast losses suggesting things could be looking up for Aemetis. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Aemetis at US$28.00 per share, while the most bearish prices it at US$19.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Aemetis' rate of growth is expected to accelerate meaningfully, with the forecast 65% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 7.7% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 3.5% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Aemetis is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Aemetis going out to 2027, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 5 warning signs for Aemetis (2 shouldn't be ignored!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.